RU95104044A - Method of treatment of upper respiratory pathway, lung and bronchi infectious diseases
- Google Patents
Method of treatment of upper respiratory pathway, lung and bronchi infectious diseases
Info
Publication number
RU95104044A
RU95104044ARU95104044/14ARU95104044ARU95104044ARU 95104044 ARU95104044 ARU 95104044ARU 95104044/14 ARU95104044/14 ARU 95104044/14ARU 95104044 ARU95104044 ARU 95104044ARU 95104044 ARU95104044 ARU 95104044A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by И.Г. Ковшик, С.В. БулавченкоfiledCriticalИ.Г. Ковшик
Priority to RU95104044/14ApriorityCriticalpatent/RU95104044A/en
Publication of RU95104044ApublicationCriticalpatent/RU95104044A/en
FIELD: medicine, pulmonology. SUBSTANCE: method involves inhalation administration of secretory immunoglobulin A as aerosol dissolved in saline solution buffered with phosphate at pH = 8.0 in lungs. EFFECT: enhanced effectiveness, decreased treatment period, decreased antibiotic and antiinflammatory drugs doses.
Claims (1)
Изобретение относится к медицине, а именно к пульмонологии, и может быть использовано для лечения инфекционных заболеваний верхних дыхательных путей, бронхов и легких. Цель изобретения - повышение эффективности, сокращение сроков лечения, снижение доз антибиотиков и противовоспалительных препаратов, применяемых в ходе лечения. Для этого ингаляторно вводят в легкие в виде аэрозоля секреторный иммуноглобулин А, растворенный в физиологическом растворе забуференного фосфатом при pH 8.0The invention relates to medicine, namely to pulmonology, and can be used to treat infectious diseases of the upper respiratory tract, bronchi and lungs. The purpose of the invention is improving efficiency, reducing treatment time, reducing doses of antibiotics and anti-inflammatory drugs used during treatment. For this, a secretory immunoglobulin A dissolved in physiological saline buffered with phosphate at pH 8.0 is inhaled into the lungs as an aerosol.
RU95104044/14A1995-03-211995-03-21Method of treatment of upper respiratory pathway, lung and bronchi infectious diseases
RU95104044A
(en)